Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

NCT05216341 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis

Interventions

DRUG: OLP-1002

Sponsor

OliPass Corporation

Collaborators

[object Object]